1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V.

    Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research . : .

    [doi:10.1158/1078-0432.CCR-23-2677]

  • Cristina-Marianini-Rios, Sanchez MEC, de Paredes AGG, Rodríguez M, Barreto E, López JV, Fuentes R, Beltrán MM, Sanjuanbenito A, Lobo E, Caminoa A, Ruz-Caracuel I, Durán SL, Olcina JRF, Blázquez J, Sequeros EV, Carrato A, Ávila JCM, Earl J.

    The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants.

    FAMILIAL CANCER . : . Nº de citas: 1

    [doi:10.1007/s10689-024-00397-w]

  • Earl J, Fuentes R, Sanchez MEC, de Paredes AGG, Muñoz M, Sanjuanbenito A, Lobo E, Caminoa A, Rodríguez M, Barreto E, López JV, Ruz-Caracuel I, Durán SL, Olcina JRF, Sánchez BL, Páez SC, Torres A, Blázquez J, Sequeros EV, Carrato A.

    The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer.

    FAMILIAL CANCER . : . Nº de citas: 1

    [doi:10.1007/s10689-024-00388-x]

  • Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MÁ, Cerezuela P, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S.

    Access to melanoma drugs in Spain: a cross-sectional survey.

    CLINICAL & TRANSLATIONAL ONCOLOGY . : . Nº de citas: 1

    [doi:10.1007/s12094-024-03501-9]

  • López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida MM, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin ML, Aicher A, García García de Paredes A, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo VJ, Heeschen C, Sainz B Jr.

    The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.

    Gut . : .

    [doi:10.1136/gutjnl-2023-330995]

  • Munoz, Eva, Alvarez, Javier Canueto, Segu, Josep Oriol Bermejo, Castano, Almudena Garcia, Guia, Vanessa Gabriela Jerviz, Lopez, Ana Maria Lopez, Sarda, Susana Puig, Jimenez, Onofre Sanmartin, Rivas, Ainara Soria, Gratal, Paula, Pardo, Teresa, Rogado, Alvaro, Berrocal, Alfonso.

    BPI24-018: Quality Recommendations for the Management of Cutaneous Squamous Cell Carcinoma (CSCC).

    Journal of the National Comprehensive Cancer Network : JNCCN . 22(2.5): .

    [doi:10.6004/jnccn.2023.7209]

  • Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, Villar MV, Caro RL, Delgado MLV, Sánchez JMS.

    SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-024-03456-x]

  • Melones-Herrero J, Alcalá S, Ruiz-Cañas L, Benítez-Buelga C, Batres-Ramos S, Calés C, Lorenzo O, Perona R, Quiroga AG, Sainz B Jr, Sánchez-Pérez I.

    Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells.

    Communications Biology . 7(1): 353-353.

    [doi:10.1038/s42003-024-06052-5]

  • Albarrán V, San Román M, Pozas J, Chamorro J, Rosero DI, Guerrero P, Calvo JC, González C, García de Quevedo C, Pérez de Aguado P, Moreno J, Cortés A, Soria A.

    Adoptive T cell therapy for solid tumors: current landscape and future challenges.

    Frontiers in immunology . 15: 1352805-1352805.

    [doi:10.3389/fimmu.2024.1352805]

  • Fernández-Argüeso M, Gómez-Bayona E, Ugalde B, Vega-Piñero B, Gil-Díaz M, Longo F, Pintor R, Botella-Carretero JI.

    Ready-to-Use Multichamber Bags in Home Parenteral Nutrition for Patients with Advanced Cancer: A Single-Center Prospective Study.

    Nutrients . 16(3): .

    [doi:10.3390/nu16030457]

  • Carrato A, Pazo-Cid R, Macarulla T, Gallego J, Jiménez-Fonseca P, Rivera F, Cano MT, Rodriguez-Garrote M, Pericay C, Alés I, Layos L, Graña B, Iranzo V, Gallego I, Garcia-Carbonero R, de Mena IR, Guillén-Ponce C, Aranda E.

    Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.

    Nejm Evidence . 3(2): 2300144-2300144.

    [doi:10.1056/EVIDoa2300144]

  • Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, Trilla-Fuertes L, Rubiolo JA, Batres-Ramos S, Vallespinos M, González-Páramos C, Rodríguez J, Gámez-Pozo A, Vara JÁF, Fernández SF, Berlinches AB, Moreno-Mata N, Redondo AMT, Carrato A, Hermann PC, Sánchez L, Torrente S, Fernández-Moreno MÁ, Mascareñas JL, Sainz B Jr.

    Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.

    Journal Of Experimental & Clinical Cancer Research . 43(1): 33-33. Nº de citas: 2

    [doi:10.1186/s13046-023-02931-7]

  • García García de Paredes A, Martínez Moneo E, Lariño-Noia J, Earl J.

    Pancreatic cancer screening in high-risk individuals.

    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS . 116(10): 519-522.

    [doi:10.17235/reed.2024.10635/2024]

  • Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C.

    A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    JOURNAL OF NEURO-ONCOLOGY . : .

    [doi:10.1007/s11060-023-04513-1]

  • Harrington KJ, Cohen EEW, Soulières D, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Swaby RF, Lin J, Ge J, Lerman N, Tourneau CL.

    Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.

    ORAL ONCOLOGY . 147: 106587-106587.

    [doi:10.1016/j.oraloncology.2023.106587]

  • Zheng Q, Tang J, Aicher A, Bou Kheir T, Sabanovic B, Ananthanarayanan P, Reina C, Chen M, Gu JM, He B, Alcala S, Behrens D, Lawlo RT, Scarpa A, Hidalgo M, Sainz B Jr, Sancho P, Heeschen C.

    Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.

    Journal Of Experimental & Clinical Cancer Research . 42(1): 323-323.

    [doi:10.1186/s13046-023-02883-y]

  • Guerrero P, Albarrán V, San Román M, González-Merino C, García de Quevedo C, Moreno J, Calvo JC, González G, Orejana I, Chamorro J, Martínez-Delfrade Í, Morón B, de Frutos B, Ferreiro MR.

    BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature.

    Cancers . 15(21): .

    [doi:10.3390/cancers15215243]

  • Alors-Pérez E, Pedraza-Arevalo S, Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Berbel I, Luque RM, Sainz B Jr, Ibáñez-Costa A, Castaño JP.

    Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential.

    Journal Of Experimental & Clinical Cancer Research . 42(1): 282-282.

    [doi:10.1186/s13046-023-02858-z]